TB-500 is not approved for human use
The Low Dose is 1.6 mg (5 units), 2-3x per week
Reported targets & pathways Angiogenesis and tissue-repair pathways (BPC-157) Actin-sequestering / cell-migration pathways (TB-500) Wound-healing signaling Tendon and muscle repair pathways Selected research Published studies on BPC-157 + TB-500 Blend Peer-reviewed references for further reading
it is a subcutaneous shot, meaning its injected under the skin
The background: In September 2023, the FDA placed nineteen peptides, including BPC-157 and TB-500, into Category 2 of its 503A bulk drug substances policy, citing safety concerns
Czechia BPC-157 purity confirmed at 99.2 % TB-500 purity confirmed above 99.8 % Assay content verified at 7.36 mg BPC-157 Assay content verified at 6.11 mg TB-500 Molecular ion mass identified at 1418 Da and 4963 Da Endotoxin level below 0.001 EU/mg No detectable heavy metals or microbial contamination Dual peptide research blend For research use only not for human or veterinary use For laboratory research only